Search results for IFITM1 antibody

IFITM1 Antibody (YA3066)(PBS only), MedChemexpress, HY-P83321A

IFITM1 Antibody (YA3066) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IFITM1.

Anti-CD225/IFITM1 Antibody (R1N85), AntibodySystem, RHC96501

HRP Anti-IFITM1 antibody [EPR22620-12], Abcam, AB306137

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

PE Anti-IFITM1 antibody [EPR22620-12], Abcam, AB306135

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

APC Anti-IFITM1 antibody [EPR22620-12], Abcam, AB306136

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Interferon Induced Transmembrane Protein 1 (IFITM1) Antibody, Abbexa, abx031068

IFN-induced antiviral protein that mediate cellular innate immunity to at least three major human pathogens, namely influenza A H1N1 virus, West Nile virus, and dengue virus by inhibiting the early step (s) of replication. Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activition or by arresting cell growth in G1 phase in a p53-dependent manner. Implicated in the control of cell growth. Component of a multimeric complex involved in the transduction of antiproliferative and homotypic adhesion signals.

Interferon Induced Transmembrane Protein 1 (IFITM1) Antibody, Abbexa, abx323804

IFITM1 Antibody is a Rabbit Polyclonal against IFITM1.

Interferon Induced Transmembrane Protein 1 (IFITM1) Antibody, Abbexa, abx113207

Interferon Induced Transmembrane Protein 1 (9-27) Antibody is a Rabbit Polyclonal antibody against Interferon Induced Transmembrane Protein 1 (9-27).

Interferon Induced Transmembrane Protein 1 (IFITM1) Antibody, Abbexa, abx234140

IFITM1 Antibody is a Rabbit Polyclonal against IFITM1.

Interferon Induced Transmembrane Protein 1 (IFITM1) Antibody, Abbexa, abx109928

Interferon-induced transmembrane protein 1 Antibody is a Rabbit Polyclonal antibody against Interferon-induced transmembrane protein 1.